Article thumbnail

Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells

By Susan Fanayan, Mona Shehata, Annelies P Agterof, Michael A McGuckin, Miguel A Alonso and Jennifer A Byrne
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2644682
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration.
  2. (2001). Alonso MA: BENE, a novel raft-associated protein of the MAL proteolipid family, interacts with Caveolin-1 in human endothelial-like ECV304 cells.
  3. (2006). Alonso MA: Dynamics of MAL2 during glycosylphosphatidylinositolanchored protein transcytotic transport to the apical surface of hepatoma HepG2 cells. Traffic
  4. (2004). Alonso MA: Expression of MAL2, an integral protein component of the machinery of basolateral to-apical transcytosis, in human epithelia.
  5. (2002). Alonso MA: MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells.
  6. (2000). Alonso MA: The MAL proteolipid is necessary for the overall apical delivery of membrane proteins in the polarized epithelial Madin-Darby canine kidney and fischer rat thyroid cell lines. Mol Biol Cell
  7. (2005). Børresen-Dale AL: Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer
  8. (2004). Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC3 cell line.
  9. (2006). Chang HY: Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet
  10. (2006). Chatterjee SK: Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncol
  11. (2001). DI: Genetic analysis of early versus late-stage ovarian tumors. Cancer Res
  12. (2003). Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
  13. (2004). Expression and distribution of MAL2, an essential element of the machinery for basolateral-to apical transcytosis in human thyroid epithelial cells. Endocrinology
  14. (2005). expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res
  15. (2004). Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest
  16. (1998). Gunning P: Identification of homoand heteromeric interactions between members of the breast carcinoma-associated D52 protein family using the yeast two-hybrid system. Oncogene
  17. (2003). H-W: Proteolipid plasmolipin: localization in polarized cells, regulated expression and lipid raft association
  18. (2001). Hakomori S: Association of MUC1 and PSGL-1 with low-density microdomain in T-lymphocytes: A preliminary note.
  19. (2002). Hemler ME: Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution and integrin-dependent cell morphology. Mol Biol Cell
  20. (2006). Hollingsworth MA: RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res
  21. (2006). Hughey RP: Recycling of MUC1 is dependent on its palmitoylation.
  22. (2001). JA: Identification of MAL2, a novel member of the mal proteolipid family, through interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics
  23. (2008). JA: Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res
  24. (2001). JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer
  25. (2006). Knuutila S: DNA copy number amplification profiling of human neoplasms. Oncogene
  26. (1997). Lidereau R: A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogenet
  27. (2006). Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. Mol Cancer Ther
  28. (2002). M: MUC1 and the immunobiology of cancer.
  29. (1997). MA: Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours.
  30. (2002). MA: MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells.
  31. (2001). MAL mediates apical transport of secretory proteins in polarized epithelial MadinDarby canine kidney cells.
  32. (2000). Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer
  33. (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA
  34. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods
  35. (2001). MUC1, the renaissance molecule.
  36. (2004). OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol
  37. (2002). Perou CM: Molecular portraits and the family tree of cancer.
  38. (2004). PM: A distinct molecular profile associated with mucinous epithelial ovarian cancer. Clin Cancer Res
  39. (2005). Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett
  40. (1995). RG: Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol
  41. (2003). RI: Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and downregulates caveolin-1. Cancer Res
  42. (1992). Rose JK: Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell
  43. (2003). Simons K: Resistance of cell membranes to different detergents.
  44. (1999). Simons K: VIP17/MAL, a lipid raft associated protein, is involved in apical transport in MDCK cells.
  45. (1995). Simons K: VIP17/MAL, a proteolipid in apical transport vesicles. FEBS Lett
  46. (2004). SJ: MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lyphoma cells and normal T cells.
  47. SM: cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation.
  48. (2004). Sprague GF Jr: A signaling mucin at the head of the Cdc42- and MAPK-dependent filamentous growth pathway in yeast. Genes Dev
  49. (2004). Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer
  50. (2000). The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer
  51. (1997). The MAL proteolipid is a component of the detergent-insoluble membrane subdomains of human T-lymphocytes.
  52. (1999). The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin-Darby canine kidney cells.
  53. (2004). The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun
  54. (2005). Towards a proteome-scale map of the human protein-protein interaction network. Nature
  55. (2005). W-S: Technology insight: Application of molecular techniques to formalin-fixed paraffinembedded tissues from breast cancer. Nat Clin Pract Oncol
  56. (2006). YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.